Literature DB >> 8933575

Advanced and controlled drug delivery systems in clinical disease management.

J R Brouwers1.   

Abstract

Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted. Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis and distally localized Crohn's disease. In cardiology the more classic controlled release systems have improved patient compliance and decreased side effects. In the treatment of intractable pain the spinal and transdermal route is well documented. In neurology the flattened peak-through levels of antiepileptic drugs and anti Parkinson's drugs represents a more predictable kinetic profile. Tracheal delivery of corticosteroids and sympaticomimetics in asthma and Chronic Obstructive Pulmonary Disease is fully accepted in clinical practice: delivery by this route results in better efficacy and a better safety profile. In gynaecology the delivery of pulsatile hormones (LHRH) is used for pregnancy induction, while transdermal oestrogens are promising in the prevention of osteoporosis. In surgical practice the use of antibiotic impregnated bone cement and antibiotic impregnated biodegradable collagens is well established. To prevent infections intravascular catheters coated with heparin or antibiotics are used. In ophthalmology the Ocusert systems provide a controlled release of different drugs in the eye. Most spectacular is the clinical introduction of the first liposomal drugs; amfotericine B and daunorubicine. Liposomal formulations of these drugs have enhanced activity and decreased toxicity compared to conventional formulations.

Entities:  

Mesh:

Year:  1996        PMID: 8933575     DOI: 10.1007/bf00820726

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  71 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  [Clinical aspects and pharmacokinetics of collagen-gentamicin as adjuvant local therapy of osseous infections].

Authors:  C von Hasselbach
Journal:  Unfallchirurg       Date:  1989-09       Impact factor: 1.000

3.  Intraocular device for cytomegalovirus infection.

Authors:  J T Ernest
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

4.  Reappraisal of the role of endotoxin in the sepsis syndrome.

Authors:  J C Hurley
Journal:  Lancet       Date:  1993-05-01       Impact factor: 79.321

5.  Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

Authors:  P S Gill; B M Espina; F Muggia; S Cabriales; A Tulpule; J A Esplin; H A Liebman; E Forssen; M E Ross; A M Levine
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

6.  Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment.

Authors:  M Bialer; S Hadad; G Golomb; S Barel; E Samara; O Abu Salach; N Berkman; H D Danenberg; J Ben David; D Caron
Journal:  Biopharm Drug Dispos       Date:  1994-01       Impact factor: 1.627

Review 7.  Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies.

Authors:  D Hollander
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

Review 8.  Radiopharmaceuticals for brain imaging.

Authors:  G B Saha; W J MacIntyre; R T Go
Journal:  Semin Nucl Med       Date:  1994-10       Impact factor: 4.446

9.  Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group.

Authors:  W B White; R J Anders; J M MacIntyre; H R Black; D A Sica
Journal:  Am J Cardiol       Date:  1995-08-15       Impact factor: 2.778

Review 10.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

View more
  4 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Mechanisms of monoclonal antibody stabilization and release from silk biomaterials.

Authors:  Nicholas A Guziewicz; Andrew J Massetti; Bernardo J Perez-Ramirez; David L Kaplan
Journal:  Biomaterials       Date:  2013-07-13       Impact factor: 12.479

3.  In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship.

Authors:  S Lin; P Y Chao; Y W Chien; S Sayani; S Kuma; M Mason; T Wes; A Yang; D Monkhouse
Journal:  AAPS PharmSciTech       Date:  2001-09-21       Impact factor: 3.246

4.  Design and Development of Fluorinated and Biocide-Free Sol-Gel Based Hybrid Functional Coatings for Anti-Biofouling/Foul-Release Activity.

Authors:  Silvia Sfameni; Giulia Rando; Maurilio Galletta; Ileana Ielo; Marco Brucale; Filomena De Leo; Paola Cardiano; Simone Cappello; Annamaria Visco; Valentina Trovato; Clara Urzì; Maria Rosaria Plutino
Journal:  Gels       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.